NanOlogy is a clinical-stage oncology company that is dedicated to improving cancer treatment and minimizing the toxic side effects associated with systemic cancer agents. They focus on delivering proven drugs directly to the tumor site through their innovative particle engineering technology platform for intratumoral drug therapy. By using their proprietary technology, NanOlogy aims to increase solid tumor response, eliminate toxicities from systemic agents, and promote favorable immunomodulation.

Their technology involves the production of stable large surface area microparticles (LSAMs) of pure drug, without any excipients or coating agents, through a unique process that combines sonication and compressed supercritical carbon dioxide. These LSAMs have a significantly large surface area to particle size ratio, allowing them to be retained at the disease site and provide continuous local drug release over time while gradually being cleared from the system at subtoxic levels. NanOlogy has already completed clinical trials for their investigational drugs LSAM-PTX and LSAM-DTX, which have shown excellent tolerability and promising signs of tumor response and immunomodulation in multiple solid tumors.

The therapeutic potential of NanOlogy's intratumoral investigational drugs spans across the cancer disease spectrum. In local disease, they offer a potential alternative to organ removal or invasive procedures by delaying or preventing solid tumor progression. In metastatic disease, these drugs have the potential to boost the local and systemic response to immunoncology therapies without adding systemic toxicity.

NanOlogy is backed by a dedicated team led by experienced professionals in the field of oncology and pharmaceuticals. With their innovative technology and diverse pipeline of products, NanOlogy is at the forefront of revolutionizing cancer treatment and improving patient outcomes